Target
Cytochrome P450 2C19
Ligand
BDBM50548670
Substrate
n/a
Meas. Tech.
ChEMBL_2022784 (CHEMBL4676597)
IC50
>10000±n/a nM
Citation
 Soth, MJLe, KDi Francesco, MEHamilton, MMLiu, GBurke, JPCarroll, CLKovacs, JJBardenhagen, JPBristow, CACardozo, MCzako, Bde Stanchina, EFeng, NGarvey, JRGay, JPDo, MKGGreer, JHan, MHarris, AHerrera, ZHuang, SGiuliani, VJiang, YJohnson, SBJohnson, TAKang, ZLeonard, PGLiu, ZMcAfoos, TMiller, MMorlacchi, PMullinax, RAPalmer, WSPang, JRogers, NRudin, CMShepard, HESpencer, NDTheroff, JWu, QXu, AYau, JADraetta, GToniatti, CHeffernan, TPJones, P Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem 63:12957-12977 (2020) [PubMed]  Article
Target
Name:
Cytochrome P450 2C19
Synonyms:
(R)-limonene 6-monooxygenase | (S)-limonene 6-monooxygenase | (S)-limonene 7-monooxygenase | CP2CJ_HUMAN | CYP2C19 | CYPIIC17 | CYPIIC19 | Cytochrome P450 2C19 (CYP2C19) | Cytochrome P450 2C19 [I331V] | Cytochrome P450-11A | Cytochrome P450-254C | Fenbendazole monooxygenase (4'-hydroxylating) | Mephenytoin 4-hydroxylase | P450-11A | P450-254C
Type:
Enzyme
Mol. Mass.:
55935.47
Organism:
Homo sapiens (Human)
Description:
P33261
Residue:
490
Sequence:
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKIYGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFMESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRGHMPYTDAVVHEVQRYIDLIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFKKSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVPPFYQLCFIPV
  
Inhibitor
Name:
BDBM50548670
Synonyms:
CHEMBL4741924
Type:
Small organic molecule
Emp. Form.:
C24H27F3N8O3
Mol. Mass.:
532.5182
SMILES:
CNC(=O)c1cn(C[C@H](F)CCc2ccc(NC(=O)Cc3cc(OC4CC(F)(F)C4)cc(C)n3)nn2)nn1 |r|
Structure:
Search PDB for entries with ligand similarity: